![ijms-22-05336-g001-550[1]](https://covint.hu/wp-content/uploads/elementor/thumbs/ijms-22-05336-g001-5501-pnlavxeimrd1vhrwe6sie3ntt77gn0n4m4ktdthfio.jpg "ijms-22-05336-g001-550[1]")
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel emerging pathogen causing an unprecedented pandemic in 21st century medicine. Due to the significant health and economic burden of the current SARS-CoV-2 outbreak, there is a huge unmet medical need for novel interventions effectively blocking SARS-CoV-2 infection. Unknown details of SARS-CoV-2 cellular biology hamper the development of potent and highly specific SARS-CoV-2 therapeutics.
![ijms-23-00796-g001-550[1]](https://covint.hu/wp-content/uploads/elementor/thumbs/ijms-23-00796-g001-5501-pnlaxaa4i57yn7swgrx3zrbsp8ijra164ui2c7gyj4.jpg "ijms-23-00796-g001-550[1]")
merging SARS-CoV-2 variants pose threats to vaccination campaigns against COVID-19. Being more transmissible than the original virus, the SARS-CoV-2 B.1.617 lineage, named the Delta variant, swept through the world in 2021. The mutations in the Delta’s spike protein shift the protein towards a net positive electrostatic potential. To understand the key molecular drivers of the Delta infection, we investigate the cellular uptake of the Delta spike protein and Delta spike-bearing SARS-CoV-2 pseudoviruses.